Goldcoin Health

Why is Goldcoin Health Foods Ltd falling/rising?

As of 10-Aug, Goldcoin Health Foods Ltd's stock price is at 29.97, reflecting a decline of 1.8% and a total drop of 6.25% over the last two days. The stock has underperformed its sector and shows signs of declining investor participation, contributing to its overall downward trend.

As of 10-Aug, Goldcoin Health Foods Ltd's stock price is falling, currently at 29.97, which reflects a decrease of 0.55 or 1.8%. The stock has underperformed its sector by 1.72% today and has been on a consecutive decline for the last two days, resulting in a total drop of 6.25% during this period. Over the past week, the stock has decreased by 4.92%, while it has also seen a significant decline of 13.13% over the past month, contrasting with a slight increase of 1.25% in the benchmark Sensex during the same timeframe.<BR><BR>Investor participation appears to be declining, as evidenced by a delivery volume of 1.2k on 06 Aug, which is down by 32.81% compared to the 5-day average. Although the stock's price is higher than its 50-day, 100-day, and 200-day moving averages, it is lower than its 5-day and 20-day moving averages, indicating a short-term weakness. Overall, these factors contribute to the current downward trend in Goldcoin Health Foods Ltd's stock price.

Which are the latest news on Goldcoin Health?

How has been the historical performance of Goldcoin Health?

Goldcoin Health has experienced a significant decline in net sales and profitability, with net sales dropping from 0.69 Cr in March 2019 to 0.07 Cr by March 2025, and negative operating profit margins. The company's financial position has worsened, reflected by negative reserves of -1.98 Cr and consistently negative cash flow from operating activities.

Answer:<BR>The historical performance of Goldcoin Health shows a declining trend in net sales and profitability over the years, with significant losses reported in recent periods.<BR><BR>Breakdown:<BR>Goldcoin Health's net sales peaked at 0.69 Cr in March 2019 but have since decreased significantly, reaching only 0.07 Cr by March 2025. The total operating income has mirrored this decline, with a high of 0.69 Cr in March 2019 dropping to 0.07 Cr in March 2025. The company's total expenditure, excluding depreciation, has fluctuated, with a notable increase to 0.21 Cr in March 2025 from 0.11 Cr in March 2023. Operating profit has remained negative, with an operating profit margin of -200.0% in March 2025, indicating a continued struggle to generate profits. The profit before tax and profit after tax have also been negative, with losses of -0.12 Cr and -0.12 Cr respectively in March 2025. The company's reserves have turned negative, reaching -1.98 Cr in March 2025, reflecting a deteriorating financial position. Total assets have decreased from 3.84 Cr in March 2020 to 2.19 Cr in March 2025, while total liabilities have also seen a decline, indicating a shrinking balance sheet. Cash flow from operating activities has been consistently negative, with no cash inflow reported in the last few years, further highlighting the company's financial challenges.

When is the next results date for Goldcoin Health?

Goldcoin Health will announce its results on 04 November 2025.

Goldcoin Health will declare its results on 04 November 2025.

How big is Goldcoin Health?

As of 24th July, Goldcoin Health Foods Ltd has a market capitalization of 4.00 Cr, with recent net sales of 0.07 Cr and a net profit loss of 0.13 Cr. As of March 2024, shareholder's funds were 1.14 Cr and total assets were 1.83 Cr.

As of 24th July, Goldcoin Health Foods Ltd has a market capitalization of 4.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Goldcoin Health reported Net Sales of 0.07 Cr. However, the company experienced a Net Profit loss of 0.13 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, where Shareholder's Funds amounted to 1.14 Cr and Total Assets were valued at 1.83 Cr.

Is Goldcoin Health overvalued or undervalued?

As of April 25, 2023, Goldcoin Health is considered risky and overvalued due to poor financial ratios, including a PE ratio of -4.71 and a ROCE of -14.00%, despite a strong one-year stock return of 106.66% and recent volatility.

As of 25 April 2023, Goldcoin Health's valuation grade has moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company is currently assessed as overvalued, given its troubling financial ratios, including a PE ratio of -4.71, an EV to EBIT of -4.47, and a ROCE of -14.00%. These figures suggest that the company is struggling to generate positive earnings and returns on capital.<BR><BR>In comparison to its peers, Goldcoin Health's valuation metrics are starkly unfavorable. For instance, MMTC has a PE ratio of 119.39, while PTC India stands out with a very attractive PE of 9.02. Additionally, Goldcoin's PEG ratio is at 0.00, which further emphasizes its lack of growth potential compared to competitors. Despite a strong one-year stock return of 106.66%, this is juxtaposed against a backdrop of negative performance in the recent week, where it declined by 6.70%, highlighting the volatility and risk associated with its current valuation.

What is the technical trend for Goldcoin Health?

As of May 12, 2025, Goldcoin Health's technical trend is bullish, supported by positive MACD, Bollinger Bands, and KST indicators, despite a bearish weekly RSI indicating some short-term weakness.

As of 12 May 2025, the technical trend for Goldcoin Health has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting a positive outlook. The Bollinger Bands also indicate bullish conditions on both time frames. However, the weekly RSI is bearish, suggesting some short-term weakness, while the monthly RSI shows no signal. The daily moving averages are bullish, reinforcing the overall positive trend. The KST is bullish on both weekly and monthly charts, and Dow Theory indicates a mildly bullish stance on both time frames. Overall, the current technical stance is bullish, with strength derived from the MACD, Bollinger Bands, and KST indicators.

Who are the top shareholders of the Goldcoin Health?

The top shareholders of Goldcoin Health include Devang P Shah with 19.49%, individual investors holding 43.54%, and Indian Clearing Corporation Limited as the largest public shareholder at 3.57%. There are no mutual funds or foreign institutional investors involved.

The top shareholders of Goldcoin Health include Devang P Shah, who is the promoter with the highest holding at 19.49%. Additionally, individual investors collectively hold 43.54% of the company. The highest public shareholder is Indian Clearing Corporation Limited, with a stake of 3.57%. There are no mutual funds or foreign institutional investors currently holding shares in the company.

Who are in the management team of Goldcoin Health?

As of March 2023, the management team of Goldcoin Health includes Devang Shah (Executive Director & Managing Director), Pravinaben (Executive Director & Wholetime Director), Ashok Solanki (Independent Non-Executive Director), and Hiren Mehta (Independent Non-Executive Director). They are responsible for the company's strategic direction and operations.

As of March 2023, the management team of Goldcoin Health consists of the following individuals:<BR><BR>1. Devang Shah - Executive Director & Managing Director<BR>2. Pravinaben - Executive Director & Wholetime Director<BR>3. Ashok Solanki - Independent Non-Executive Director<BR>4. Hiren Mehta - Independent Non-Executive Director<BR><BR>These members play key roles in guiding the company's strategic direction and operations.

What does Goldcoin Health do?

Goldcoin Health Foods Ltd is a micro-cap company trading primarily in milk products within the FMCG industry. As of March 2025, it reported net sales and profit of 0 Cr, with a market cap of Rs 5 Cr.

Overview: <BR>Goldcoin Health Foods Ltd is engaged in the trading of food products, primarily milk, and operates within the FMCG industry as a micro-cap company.<BR><BR>History: <BR>Goldcoin Health Foods was incorporated as a private limited company in March 1989 and transitioned to a public limited company in March 1995. The latest quarterly results reported net sales and net profit of 0 Cr for March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 5 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 30 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.24 <BR>Return on Equity: -12.75% <BR>Price to Book: 4.85<BR><BR>Contact Details: <BR>Address: 66/392 Pragatinagar, Naranpura Ahmedabad Gujarat : 380013 <BR>Email: goldcoinhealth@gmail.com <BR>Website: http://www.goldcoinhealthfoods.com

Has Goldcoin Health declared dividend?

No Dividend History Available

Who are the peers of the Goldcoin Health?

Goldcoin Health's peers include Hind. Unilever, ITC, Nestle India, Britannia Inds., Godrej Consumer, Tata Consumer, Dabur India, Colgate-Palmoliv, and Godfrey Phillips. Goldcoin Health has the highest 1-year return at 131.81%, while its peers show varying management risks and growth rates.

Peers: The peers of Goldcoin Health are Hind. Unilever, ITC, Nestle India, Britannia Inds., Godrej Consumer, Tata Consumer, Dabur India, Colgate-Palmoliv, and Godfrey Phillips.<BR><BR>Quality Snapshot: Excellent management risk is observed at ITC, Nestle India, Britannia Inds., and Colgate-Palmoliv, while Good management risk is found at Hind. Unilever, Godrej Consumer, and Dabur India. Average management risk is present at Tata Consumer, while Godfrey Phillips has Good growth, and the rest have Below Average growth. All peers have Excellent capital structure except for Goldcoin Health, which does not qualify.<BR><BR>Return Snapshot: Godfrey Phillips has the highest 1-year return at 123.75%, while Dabur India has the lowest at -10.99%. Goldcoin Health's 1-year return of 131.81% is significantly higher than all peers. Additionally, Dabur India and Colgate-Palmoliv have negative six-month returns.